Perioperative chemotherapy for clinical stage IIIB gallbladder cancer: a review of the National Cancer Database
International Journal of Clinical Oncology · 2026-07 · 31 (7) · 1345-1354
DOI: 10.1007/s10147-026-03051-w ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, online erschienen am 28.05.2026. Verfasst von Jennifer Wylie und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wake Forest School of Medicine, Winston Salem, NC, USA. Jennifer.wylie@advocatehealth.org. Hauptthemen laut MEDLINE: Gallbladder Neoplasms. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Wake Forest University.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Gallbladder cancer is rare with high mortality and limited treatments. Patients with IIIB disease (T1-3, N1, M0) are typically not offered resection and may receive palliative chemotherapy. This study evaluates survival of IIIB patients undergoing surgery with or without systemic therapy.
Methods
Patients with stage IIIB gallbladder cancer who underwent curative-intent surgery were identified from the National Cancer Database (2004–2020). Outcomes were analyzed by chemotherapy sequence using Kaplan-Meier curves and Cox proportional hazards models. Lymphadenectomy type and margin status were also compared.
Results
409 patients were included. Mean age was 60 in neoadjuvant, 65 in adjuvant and 72 in no chemotherapy classes ( p < 0.01). The median overall survival (OS) in months was 33.8 (95% CI 23.8 - NA) in neoadjuvant, 22.6 (95% CI 19.8–27.2) in adjuvant and 9.4 (95% CI 7.3–14.3) in no chemotherapy groups ( p < 0.01). Compared to adjuvant therapy, hazard ratios (HR) for OS were 0.76 (95% CI 0.46–1.26, p = 0.29) for neoadjuvant and 1.87 (95% CI 1.45–2.42, p < 0.01) for no chemotherapy. Age, tumor size, number of positive regional nodes, and positive margins (R1) were significant covariables. Regional lymphadenectomies were performed in 79%, 87%, and 84% for neoadjuvant, adjuvant, and no chemotherapy classes. R0 margins were obtained in 86%, 76%, and 81%, respectively.
Conclusion
Surgery with systemic therapy should be considered in stage IIIB gallbladder cancer. Perioperative chemotherapy was associated with longer survival but occurred more in younger patients. Perioperative chemotherapy, particularly neoadjuvant, may benefit appropriately selected patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wake Forest School of Medicine, Winston Salem, NC, USA. Jennifer.wylie@advocatehealth.org.
- Medical Center Blvd Winston Salem, Winston-Salem, 27157, NC, USA. Jennifer.wylie@advocatehealth.org.
- Premier Surgical Associates at Fort Sanders Regional Medical Center, Knoxville, TN, USA.
- Wake Forest School of Medicine, Winston Salem, NC, USA.
- Virginia Mason Medical Center, Seattle, WA, USA.
Förderung
- NCI NIH HHS
- Wake Forest University
Zitieren
APA
Wylie, J., Leonard, G., White, B., Clark, C., Levine, E., & Shen, P. (2026). Perioperative chemotherapy for clinical stage IIIB gallbladder cancer: a review of the National Cancer Database. International Journal of Clinical Oncology, 31(7), 1345-1354. https://doi.org/10.1007/s10147-026-03051-w
Vancouver
Wylie J, Leonard G, White B, Clark C, Levine E, Shen P. Perioperative chemotherapy for clinical stage IIIB gallbladder cancer: a review of the National Cancer Database. International Journal of Clinical Oncology. 2026;31(7):1345-1354. doi:10.1007/s10147-026-03051-w
BibTeX
@article{Wylie2026,
author = {Wylie, Jennifer and Leonard, Grey and White, Brian and Clark, Clancy and Levine, Edward and Shen, Perry},
title = {Perioperative chemotherapy for clinical stage IIIB gallbladder cancer: a review of the National Cancer Database},
journal = {International Journal of Clinical Oncology},
year = {2026},
volume = {31},
number = {7},
pages = {1345--1354},
doi = {10.1007/s10147-026-03051-w}
}
EUVIMED